相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Aromatase Inhibitors-Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects
Sara Tenti et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches
Bente Langdahl
BONE (2020)
Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study
Marta Pineda-Moncusi et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline
Charles L. Shapiro et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Osteoporosis treatment and 10 years' oestrogen receptor plus breast cancer outcome in postmenopausal women treated with aromatase inhibitors
B. Bouvard et al.
EUROPEAN JOURNAL OF CANCER (2018)
Global Cancer Incidence and Mortality Rates and Trends-An Update
Lindsey A. Torre et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2016)
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Nadia Howlader et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Clinician's Guide to Prevention and Treatment of Osteoporosis
F. Cosman et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
R. Coleman et al.
ANNALS OF ONCOLOGY (2013)
Bone health in breast cancer survivors
Hikmat Abdel-Razeq et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2011)
Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study
George Ioannidis et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2009)
Zoledronic Acid Effectively Prevents Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results
Adam M. Brufsky et al.
CLINICAL BREAST CANCER (2009)
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole
Nigel J. Bundred et al.
CANCER (2008)
Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230
Richard Eastell et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCICCTG MA.17
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Effect of screening and adjuvant therapy on mortality from breast cancer
DA Berry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study
SCE Schuit et al.
BONE (2004)
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer - Results of the ATAC (arimidex, tamoxifen alone or in comhination) trial efficacy and safety update analyses
CANCER (2003)
Bone loss and bone size after menopause
HG Ahlborg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
分享论文
